The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...

Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...